The patient was diagnosed with a kidney tumor at the age of seven. Over the following decade, the disease returned repeatedly and developed widespread metastases. By the time he was considered for the experimental treatment, large tumor masses had formed in the abdominal cavity, while additional lesions were present in the lungs, liver, pelvis, and brain. Standard therapies had failed to produce a durable cure, and no suitable clinical trial or established treatment option remained. Molecular profiling performed through the INFORM pediatric tumor-sequencing program identified a potentially exploitable feature of the cancer: the tumor cells produced PRAME, short for Preferentially Expressed Antigen in Melanoma, a protein that is normally absent or present only at very low levels in most healthy tissues but is frequently activated in cancer.

PRAME has attracted considerable interest as an immunotherapy target because its restricted distribution in normal tissues may create a therapeutic window. The protein is found in a range of adult malignancies, including melanoma, sarcomas, and several other aggressive cancers. It has also been detected in high-risk pediatric tumors. In the INFORM database, which includes molecular data from more than 2,500 children and adolescents with cancer, PRAME appears in many tumors for which treatment options are limited. The protein is produced inside cancer cells and can be processed into short fragments that are displayed on the cell surface by human leukocyte antigen molecules. T cells equipped with a suitable antigen-recognition system can potentially identify these fragments and destroy the cells presenting them.

The Heidelberg team used the patient’s own T cells as the starting material for the treatment. In the laboratory, the cells were genetically modified so that they could recognize PRAME on tumor cells and mount a targeted immune response. The genetic instructions were delivered using a vector supplied by Immatics, a biotechnology company based in Tübingen that has developed PRAME-directed T-cell platforms and has tested related approaches in adults. The modified cells were manufactured locally at the National Center for Tumor Diseases in Heidelberg in a seven-day process. After preparatory treatment to create space for the infused cells within the immune system, the patient received the personalized cellular product in July 2025.

The biological response was visible almost immediately. Nine days after infusion, a biopsy of a tumor lesion revealed extensive infiltration by the engineered T cells. The sample also showed widespread death of malignant cells, suggesting that the modified immune cells had reached the tumor and were actively exerting their intended effect. During the weeks and months that followed, tumor deposits regressed across all affected organs. A second biopsy, obtained three months after treatment, contained no detectable living tumor cells. Serial imaging studies and blood analyses have since found no evidence of active cancer, according to the treating physicians. The report does not establish that the patient is permanently cured, but the depth and breadth of the response are highly unusual in a disease that had continued to progress despite multiple lines of therapy.

Almost a year after the infusion, the patient, identified in accompanying materials as Mailo, was reported to be in excellent physical condition. He has resumed regular mountain-bike training and participated in cycling competitions, completed his vocational training, and is preparing to pursue his Abitur, the German university-entrance qualification. Such recovery is especially notable given the extent of his disease before treatment. At the same time, the investigators emphasize that this is a single compassionate-use case rather than evidence that PRAME-specific T-cell therapy is effective for all pediatric cancers. Responses can depend on the amount of target antigen expressed by a tumor, the patient’s HLA type, the ability of engineered cells to enter solid tumor tissue, and the capacity of cancer cells to evade immune recognition.

The treatment also illustrates the technical challenges of bringing cell therapy to children with solid tumors. Unlike many blood cancers, solid tumors are embedded in complex tissue environments that can restrict immune-cell entry and suppress T-cell activity. Tumor cells may lose or reduce the target antigen, alter antigen presentation, or create an immunosuppressive environment that limits cellular persistence. The Heidelberg biopsy results are therefore important because they provided direct evidence that the engineered cells penetrated the tumor and were associated with malignant-cell destruction. Further studies will need to determine how long the modified T cells remain in the body, whether they establish immune memory, and how frequently resistance or relapse occurs after an initial response.

Building on the case, KiTZ is preparing a first Phase I/II clinical trial called PRAMEtime for children and adolescents with PRAME-positive solid tumors. The study is planned to enroll up to 18 patients between eight and 17 years of age, with a projected start in 2027. Participants will receive their own genetically modified immune cells, produced through the collaboration with Immatics. In future projects, manufacturing is expected to be supported by the Center for Innovative Therapies in Heidelberg, established by Heidelberg University Hospital and the DKFZ in June 2026, while Immatics will continue to provide the vector used to reprogram T cells for PRAME-positive tumors. The early-phase trial will primarily assess safety, feasibility, dosing, cellular persistence, and preliminary signs of antitumor activity.

The PRAMEtime program is being supported by approximately 1.8 million euros from the Dietmar Hopp Foundation over four years at the Heidelberg Medical Faculty of Heidelberg University. Academic funding is particularly important in pediatric oncology, where individual tumor types are rare and patient populations are too small to attract extensive commercial investment. The project also demonstrates the increasingly interdependent relationship between biotechnology companies and academic hospitals: industry partners can supply sophisticated molecular tools and vectors, while specialist cancer centers identify suitable patients, manufacture cellular products, perform intensive monitoring, and investigate the biological reasons for response or treatment failure. If the planned trial confirms that PRAME-directed cells can be administered safely and repeatedly benefit children with otherwise incurable solid tumors, the approach could become a foundation for broader pediatric cellular-immunotherapy studies. For now, the adolescent’s recovery remains an exceptional result—but one that has transformed a promising laboratory target into a clinically testable strategy for a group of patients with few remaining options.

Subject of Research: Personalized PRAME-specific genetically modified T-cell therapy for advanced, treatment-resistant pediatric nephroblastoma and other PRAME-positive solid tumors.

Article Title: PRAME-Specific T-Cell Therapy in Advanced Pediatric Nephroblastoma

News Publication Date: 13 August 2026

Web References: https://doi.org/10.1056/NEJMc2605154

References: K. Mair et al., “PRAME-Specific T-Cell Therapy in Advanced Pediatric Nephroblastoma,” New England Journal of Medicine, online publication 13 August 2026. DOI: 10.1056/NEJMc2605154

Image Credits: Image 1: private. Image 2: @mailo.grh.

Keywords: pediatric cancer, nephroblastoma, Wilms tumor, PRAME, T-cell therapy, cellular immunotherapy, gene-modified T cells, solid tumors, personalized medicine, immuno-oncology, KiTZ Heidelberg, DKFZ, Immatics, compassionate use, PRAMEtime

The review by Li, Zhu, Shen and colleagues examines two main routes for producing therapeutic immune cells. The first begins with peripheral blood mononuclear cells, a mixed population that includes lymphocytes and monocytes collected from a patient or donor. These cells can be isolated, activated and genetically modified before being returned to the recipient. The second route uses stem cells as a renewable starting material. Haematopoietic stem cells, which naturally generate blood and immune cells, can be expanded or redirected, while pluripotent stem cells can be differentiated into specialized immune populations under controlled laboratory conditions.

This distinction is important because conventional autologous cell therapies are laborious and variable. In an autologous process, a patient’s cells are collected, engineered and expanded before treatment. Disease, age, prior therapies and the condition of the patient’s immune system can all affect the quality and quantity of the starting material. Allogeneic manufacturing instead uses cells from a donor or a banked stem-cell line. A single engineered cell source may therefore be used to produce multiple treatment doses, allowing manufacturing to be performed in advance and under tightly controlled conditions.

Stem-cell engineering has expanded the range of immune cells that can be produced for therapy. T cells remain a central focus because they can identify abnormal cells through antigen-specific receptors and destroy them through cytotoxic mechanisms. Natural killer cells provide another route to immune-mediated killing and can recognize stressed or transformed cells without relying on the same antigen-recognition system as conventional T cells. Macrophages, which engulf material and influence inflammation, are also being developed as therapeutic agents. Each cell type offers distinct biological advantages, but each presents different challenges in generating a stable, potent and clinically useful product.

One of the most prominent technologies discussed in this field is the chimeric antigen receptor, or CAR. A CAR is a synthetic receptor introduced into an immune cell through genetic engineering. Its external binding region is designed to recognize a selected molecular marker, while internal signalling domains activate the cell after target engagement. CAR engineering has been particularly influential in T-cell therapy, but researchers are also adapting the technology for natural killer cells and macrophages. These CAR-equipped cells are intended to improve target recognition, strengthen activation and potentially overcome mechanisms that allow diseased cells to evade natural immunity.

Genetic modification can also be used to improve safety and immune compatibility. Researchers are investigating edits that reduce the ability of donor-derived cells to attack healthy recipient tissues, a complication associated with immune recognition across individuals. Other modifications may limit the capacity of therapeutic cells to trigger excessive inflammation, a process that can produce serious systemic effects. Gene engineering can additionally introduce “safety switches” or other control systems designed to eliminate or deactivate the cells if unwanted toxicity occurs. At the same time, reducing the expression of molecules recognized by the recipient’s immune system may help prolong the survival of transplanted cells.

The review also highlights the importance of differentiation platforms. Producing an immune cell from a stem cell is not simply a matter of adding one factor to a culture. Cells must receive carefully timed combinations of signalling molecules, growth factors and environmental cues that reproduce aspects of blood-cell development. Scientists are refining three-dimensional culture systems, feeder-free methods and scalable bioreactors to control this process. The objective is to generate large numbers of cells with a uniform identity, predictable function and minimal contamination by unwanted or incompletely differentiated cell types.

Manufacturing remains one of the field’s decisive tests. A clinically compatible process must preserve cell viability and activity while meeting strict standards for sterility, genetic stability and product consistency. Cells may need to be frozen, transported and stored without losing their therapeutic properties. Stem-cell-derived products also require extensive characterization to confirm that residual undifferentiated cells do not create safety risks. Advances in automation, closed-system processing and analytical technologies are helping researchers move from small laboratory batches toward reproducible production at a scale suitable for clinical use.

Early clinical evidence is beginning to shape expectations, but the review emphasizes that important questions remain. Researchers must determine how long engineered cells persist in the body, whether they continue functioning after repeated exposure to disease environments and how reliably they reach the tissues where they are needed. Tumours and chronic inflammatory conditions can suppress immune activity, while infectious diseases may impose rapidly changing biological pressures. Future studies will need to compare cell sources, genetic designs and manufacturing strategies directly, while also monitoring delayed toxicities and the long-term consequences of genome editing.

Together, these developments suggest that allogeneic immunotherapy could become a flexible platform rather than a single treatment type. Donor-derived and stem-cell-derived T cells, natural killer cells, macrophages and CAR-engineered variants may eventually be selected according to the disease, target and desired immune response. The review presents this convergence of gene engineering, stem-cell biology and bioprocessing as a foundation for more accessible cellular medicines. Its central message is that therapeutic success will depend not only on making immune cells powerful, but also on making them controllable, compatible, manufacturable and safe enough for broad clinical application.

Subject of Research: Allogeneic immunotherapy using genetically engineered and stem-cell-derived immune cells

Article Title: Allogeneic immunotherapy

Article References: Li, YR., Zhu, Y., Shen, X. et al. Allogeneic immunotherapy. Nat Rev Bioeng (2026). https://doi.org/10.1038/s44222-026-00468-w

Image Credits: AI Generated

DOI: 10.1038/s44222-026-00468-w

Keywords: Allogeneic immunotherapy, cell-based immunotherapy, stem cell engineering, T cells, natural killer cells, macrophages, CAR-engineered cells, gene editing, pluripotent stem cells, therapeutic cell manufacturing